Global Rilonacept Drugs Market Overview:
Rilonacept is a dimeric fusion protein made up of the extracellular ligand-binding domains of the human interleukin-1 receptor segment (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP) connected in-line to the Fc portion of human IgG1. Rilonacept-based drug ARCALYST is a prescription drug known as an interleukin-1 (IL-1) antagonist. Cryopyrin-associated intermittent syndromes (CAPS), such as familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome, are treated with this drug (MWS). ARCALYST comes in single-use 20-mL glass vials of a sterile, off-white lyophilized powder. ARCALYST should be reconstituted with 2.3 mL of Sterile Water for Injection per vial. Patients taking ARCALYST have developed serious illnesses, including life-threatening infections and death. Rilonacept is a drug that is used to treat a variety Drugs may have an effect on the immune system, reducing the ability to combat pathogens.
- Prevalence of Familial cold autoinflammatory syndrome (FCAS)
- Rising Geriatric Population
- Technical Progress in Medical Industry
- Side Effects and Adverse Reactions
The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Kiniksa Pharmaceuticals, Ltd. (Bermuda) and Regeneron Pharmaceuticals (United States). Considering Market by Treatment, the sub-segment i.e. Familial Cold Urticaria Syndrome (FCUS) will boost the Rilonacept Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharma will boost the Rilonacept Drugs market.
On 18th March, 2021 - Received US Food and Drug Administration (FDA) Clearance for ARCALYST (Rilonacept) for the Treatment of Recurrent Pericarditis and Reduction in Risk of Recurrence in Adults and Children 12 Years and Older.
European Medicines Agency, EU/3/07/456; Revoked - Orphan Designation Granted to Regeneron UK Ltd., For Its Rilonacept Drug Was Withdrawn by the European Commission on 24 October 2012. The Drug Is No Longer Valid for Sale Across EU. and United States, Food and Drug Administration “ARCALYST/Rilonacept” Label; Provides a Comprehensive List of Procedures Regarding the Usage, Indications and Dosage Requirements Based on the Patient Profile of ARCALYST Injections Across US.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Rilonacept Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Rilonacept Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, API Providers, Rilonacept Drugs Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.